![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will be used to fund development of SBS-518, a first-in-class dual sigma receptor (SR) antagonist/dopamine transporter (DAT) inhibitor in development for the treatment of stimulant use disorder, from IND submission through Phase 1 clinical development.
Lead Product(s): SBS-518
Therapeutic Area: Psychiatry/Psychology Product Name: SBS-518
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: $19.0 million Upfront Cash: Undisclosed
Deal Type: Funding August 08, 2023